7/22/2023 0 Comments Alopecia totalis universalisWashington, DC: United States Department of Labor. Consumer Price Indexes-All Urban Consumers. ![]() Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Validation of case identification for alopecia areata using international classification of diseases coding. Lavian J, Li SJ, Lee EY, Bordone LA, Polubriaginof FCG, Christiano AM, et al. Economic burden and healthcare resource use of alopecia areata in an insured population in the USA. Mostaghimi A, Xenakis J, Meche A, Smith TW, Gruben D, Sikirica V. Comorbidities in alopecia areata: a systematic review and meta-analysis. Systemic treatments for alopecia areata: A systematic review. Guidelines for the management of alopecia areata. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG, British Association of Dermatologists. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010 62(2):191-202.ģ.Ělkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Clin Cosmet Investig Dermatol 2015 8:397-403.Ģ.Ělkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Epidemiology and burden of alopecia areata: a systematic review. ![]() Over 50% more patients with AT/AU received immunosuppressive agents than patients with non-AT/AU AA.Ĭonclusion: Patients with AT/AU had higher rates of comorbidities and greater healthcare resource utilization medical costs than patients with non-AT/AU AA, suggesting that improved insight into the patterns of specific comorbid conditions is needed.ġ. Post-index patients with AT/AU had higher per person per policy year healthcare resource utilization and costs ( P≤0.001) and total adjusted annual mean costs ( P<0.05). More patients with AT/AU had baseline comorbidities (atopic disease, anemia, autoimmune disorders P≤0.001 for all). Compared with patients with non-AT/AU AA (n=13,116), patients with AT/AU were older (mean age 43.1 vs 40.6 years, P<0.0001) and more were female (68.1% vs 62.9%, P<0.0001). Results: 14,340 patients with AA were identified, including 1,224 patients with AT or AU. Baseline characteristics measured at first AA diagnosis (index date) and all-cause healthcare utilization and costs identified in the 1-year post-index period were compared between AT/AU and non-AT/AU AA cohorts. Methods: Using a large US administrative healthcare claims database, two mutually exclusive patient cohorts were identified: AA cohort: ≥1 diagnosis of AA AT/AU cohort: ≥1 diagnosis of AT/AU between January 1 and December 31, 2017. Limited information exists about the cost and healthcare burden of AT and AU. Extensive forms of AA include alopecia totalis (AT complete scalp hair loss) or alopecia universalis (AU complete scalp, face, and body hair loss). ![]() Background: Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss.
0 Comments
Leave a Reply. |